iRhythm

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

To provide superior clinical service for patients.

Our vision is to continue to empower clinicians with actionable insights to provide better personalized arrhythmia care for patients.

iRhythm has been recognized by numerous awards, including the 2019 Goldman Sachs 200 Investment as one of the best private companies in America and the 2018 Goldman Sachs 100 Investment for its innovation in healthcare. The company was also recognized as one of the most promising health technology companies in 2017 by Silicon Review.